SCLC1, small cell cancer of the lung, 7864

N. diseases: 73; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.070 Biomarker phenotype BEFREE STAS was associated with distant metastasis, as well as with higher CIR and LC-CID in the overall cohort and in the AC, LCNEC, and SCLC cohorts (owing to a small number of recurrences and deaths [<5], prognostic analysis was not performed in the TC cohort). 31121325 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.070 Biomarker phenotype BEFREE In conclusion, ED-SCLC with metastasis limited to the brain could be treated with curative intent. 31135898 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.070 GeneticVariation phenotype BEFREE After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel. 28193529 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.070 Biomarker phenotype BEFREE SCLC is a lethal neuroendocrine tumor type that is highly prone to metastasis. 28007623 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.070 Biomarker phenotype BEFREE NRG Oncology RTOG 0937 is a randomized phase II trial evaluating 1-year overall survival (OS) with prophylactic cranial irradiation (PCI) or PCI plus consolidative radiation therapy (PCI+cRT) to intrathoracic disease and extracranial metastases for extensive-disease SCLC. 28648948 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.070 Biomarker phenotype BEFREE It suggests that SCLC evolving from the same stem cell as NSCLC should be differentiated into primary and secondary tumors. 11455030 2001
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.070 Biomarker phenotype BEFREE Our observation suggests that this assay may be useful in diagnosing metastatic disease and monitoring minimal residual disease in patients with SCLC. 10810412 2000